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Capsule summary 43 
What is already known on this topic: Case reports suggest an association between dipeptidyl 44 
peptidase-IV inhibitors and development of bullous pemphigoid. 45 
What this article adds to our knowledge: This case-control study confirms an increased risk of 46 
developing bullous pemphigoid in patients receiving dipeptidyl peptidase-IV inhibitors. 47 
How this information impacts clinical practice and/or changes patient care: Dipeptidyl 48 
peptidase-IV inhibitors, especially vildagliptin, should be used cautiously in high-risk diabetic 49 
patients, ie. males and older than 80 years.    50 
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Abstract 51 
Background: Case reports have suggested an association between dipeptidyl peptidase-IV 52 
inhibitors (DPP4i) and development of bullous pemphigoid (BP).  53 
Objective: To evaluate the association between DPP4i treatment and development of BP. 54 
Methods: We conducted a retrospective 1:2 case-control study, comparing diabetic BP cases 55 
to age and sex-matched diabetic controls, issued from Swiss (Bern) and French (Marseille) 56 
dermatological departments, from January 1st 2014 to July 31st 2016.   57 
Results: We collected 61 diabetic BP patients and 122 controls. DPP4i were associated with 58 
an increased risk of developing BP (adjusted OR=2.64; 95% CI: 1.19-5.85; p=0.02), with 59 
vildagliptin showing the highest adjusted OR (3.57; 95% CI: 1.07-11.84; p=0.04). Stratified 60 
analysis showed a stronger association in males and patients aged 80 years or older. DPP4i 61 
withdrawal and the institution of first-line treatments led to clinical remission in 95% of 62 
cases. 63 
Limitations: This was a retrospective study in tertiary referral hospitals. We focused the 64 
analysis on DPP4i intake, without analyzing the potential isolated effect of metformin.  65 
Conclusions: DPP4i, especially vildagliptin, are associated with an increased risk of 66 
developing BP. Their use needs to be carefully evaluated, particularly in high-risk patients, 67 
such as males and those aged 80 years or older.   68 
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Introduction 69 
Bullous pemphigoid (BP) is the most frequent autoimmune subepidermal blistering disease 70 
which typically affects the elderly. Its cutaneous manifestations are polymorphic, ranging 71 
from pruritus with excoriated, eczematous, papular and/or urticaria-like lesions in the non-72 
bullous phase, to vesicles and bullae in the bullous phase (1). BP is associated with an 73 
immune response directed against two molecules, the BP antigen 180 (BP180, BPAG2), and 74 
the BP antigen 230 (BP230, BPAG1) (2).  75 
Since the publication of the first case of BP associated with sulfasalazine in 1970, a wide 76 
range of drugs (spironolactone, furosemide, chloroquine, beta-blockers and several 77 
antibiotics) have been associated with the disease (3). Recently, several cases of BP have been 78 
reported in association with dipeptidyl peptidase-IV inhibitors (DPP4i), also known as 79 
gliptins (7-16). 80 
DPP4i are oral anti-hyperglycemic drugs administered to patients with type 2 diabetes in 81 
monotherapy or in combination with other oral anti-hyperglycemic medications or insulin. 82 
DPP4 is an enzyme that inactivates incretins (glucagon-like peptide-1 and glucose-dependent 83 
insulinotropic polypeptide). DPP4i increase levels of incretins, thereby increasing insulin 84 
secretion, decreasing glucagon secretion and improving glycemic control. Sitagliptin was first 85 
approved in 2006 by the U.S. Food and Drug Administration, followed by saxagliptin (2009), 86 
linagliptin (2011) and alogliptin (2013). Three DPP4i are currently available on the French 87 
market and five DPP4i on the Swiss market: sitagliptin and vildagliptin (2007), saxagliptin 88 
(2009) and, only on Swiss market, linagliptin (2011) and alogliptin (2013). They are used 89 
alone or in association with metformin in the same tablet (7).  90 
An increasing number of clinical reports and pharmacovigilance database analyses have been 91 
published, suggesting an association between DPP4i intake and BP. Nevertheless, this has not 92 
been confirmed by a well-designed controlled study. 93 
The main objective of our case-control study was, therefore, to retrospectively evaluate the 94 
association between DPP4i treatment and development of BP. The secondary endpoints were 95 
to determine a potential higher association for a specific DPP4i, and to evaluate the disease 96 
course after DPP4i withdrawal.  97 
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Materials and methods 98 
The investigations were conducted as a retrospective case-control study with 1:2 design, 99 
comparing BP diabetic cases to age and sex-matched type 2 diabetic controls, from January 100 
1st 2014 to July 31st 2016. All study procedures adhered to the Declaration of Helsinki 101 
Principles. The French committee for the protection of persons (RO-2016/37) and the ethics 102 
committee of the Canton of Bern (KEK-2016/01488) approved the study. The French 103 
advisory committee on information processing in material research in the field of health 104 
(CCTIRS) and the French commission for information technology and civil liberties (CNIL) 105 
also authorized this study. 106 
 107 
Data collection for cases and controls 108 
The study was conducted in three University dermatological departments (Bern, Marseille 109 
Nord, and Marseille La Timone). By using the database of the respective histopathology 110 
departments and clinical records, we identified all patients with BP diagnosed for the first 111 
time between January 1st 2014 and July 31st 2016. The diagnosis of BP was based on the 112 
following criteria, developed by the French bullous study group (4): consistent clinical 113 
features, compatible histopathology findings, positive direct immunofluorescence (DIF) 114 
studies and in some cases, positive indirect immunofluorescence microscopy (IIF) studies 115 
and/or positive ELISA-BP180/ELISA-BP230 (MBL International, Japan). Among these BP 116 
patients, we identified the cases having type 2 diabetes. 117 
 118 
For these patients, we recorded: age, sex, date of BP diagnosis, treatment of BP (topical 119 
steroids, systemic corticosteroids, immune suppressors, other treatments such as doxycycline 120 
or dapsone), evolution of BP (complete remission, partial remission, relapse, death), 121 
comorbidities (rheumatic, neurological, cardio-vascular, digestive diseases, neoplasia, etc.), 122 
treatment with DPP4i, and other co-treatments (diuretics, antibiotics, neuroleptics, NSAID, 123 
antihypertensive drugs, etc.).  124 
If a DPP4i was mentioned in the medical record, we examined the type of DPP4i, the 125 
chronology between BP diagnosis and onset of the DPP4i treatment, and the evolution after 126 
DPP4i withdrawal. Patients suffering from other autoimmune bullous diseases, or who did not 127 
otherwise fulfill the inclusion criteria, were not included.  128 
 129 
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The controls were obtained between January 1st 2014 and July 31st 2016 from the 130 
endocrinology departments of the same hospitals. For each case, two diabetic control patients, 131 
visiting the endocrinology department in the same 6-month period and matched to the case by 132 
gender and quinquennium of age, were then randomly selected from all available patients 133 
satisfying the matching criteria. The patient files were reviewed concerning treatment for 134 
diabetes, specifically the use of DPP4i, other co-treatments and comorbidities. For the 135 
controls, we did not include patients suffering at the time of the study from any chronic skin 136 
diseases, including bullous dermatosis. 137 
We then compared exposure to DPP4i between cases and controls with adjustment for 138 
potential confounders. 139 
 140 
Statistical analysis 141 
Descriptive data were presented as number with percentages or means with standard 142 
deviations (SD) for categorical and continuous variables respectively. Mann-Whitney U test 143 
was used to assess possible residual differences in the distribution of age between cases and 144 
controls. Differences between cases and matched controls across different levels of other 145 
factors were assessed by means of univariate conditional logistic regression analysis. Factors 146 
associated to DPP4i use were also investigated by means of Pearson’s χ2 test or Fisher’s exact 147 
test, where required. 148 
All factors with p-value <0.10 in the univariate case-control analysis and associated to DPP4i 149 
use, with p-value <0.10 at univariate level, were evaluated as possible confounding factors in 150 
multivariate conditional logistic regression models with backward stepwise selection 151 
algorithm. Factors retained for adjustment were: neurological and metabolic/endocrine 152 
comorbidities, as well as other dermatological conditions unrelated with BP. The effect of 153 
DPP4i use on BP onset in diabetic patients was expressed in terms of odds ratio (OR) along 154 
with its 95% confidence interval (CI) and p-value. A stratified analysis by possible effect 155 
modifiers, including gender and age group, was also performed. All tests were considered 156 
statistically significant at p-value <0.05. 157 
Before starting the study, we planned to recruit at least 183 patients (61 cases and 122 158 
controls) in order to detect OR >2.5 in a 1:2 matched case-control design, supposing to 159 
observe a 30% exposure to DPP4i use in the control group, (α=0.05, β=0.20, multiple 160 
correlation coefficients <0.2). Analyses were carried out by using SPSS software v. 20.0 161 
(Armonk, NY: IBM Corp.).  162 
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Results 163 
From January 2014 to July 2016, 165 patients were diagnosed with BP (61 in Bern, 47 in 164 
Marseille Nord and 57 in Marseille La Timone). Among these, 61 were diabetic (22 in Bern, 165 
14 in Marseille Nord and 25 in Marseille La Timone). We collected two matched controls for 166 
each case, resulting in a total of 122 controls. 167 
50.8% of cases were females and the mean age was 79.1 ± 7.0 years. The main comorbidities 168 
of cases were cardio-vascular (86.9%), neurological (52.5%), metabolic and endocrine, other 169 
than diabetes (39.3%) and uronephrological diseases (39.3%) (Table 1). 170 
In our three investigational centers, we collected 28 diabetic patients with BP on DPP4i. 171 
DPP4i were used more frequently in BP cases (45.9%) than in controls (18%) and the 172 
difference was statistically significant (p <0.001). Of the specific DDP4i, vildagliptin was 173 
more common in cases (23%) compared to controls (4.1%). For the other co-treatments, there 174 
was no statistical difference between cases and controls, except for the use of antihistamines 175 
(p <0.001). There were no differences in other anti-diabetic medications, including 176 
metformin, between cases and controls (p=0.08) (Table 2). 177 
All cases of BP received high potency topical steroids as first line treatment. Systemic 178 
corticosteroids were used in half of cases (50.8%), immunosuppressive agents in 32.8% of 179 
cases, and other treatments such as doxycycline or dapsone in 34.4% of cases. With treatment, 180 
37.7% went into complete remission and 42.6% went into partial remission. Finally, there 181 
were no differences in treatment between the DPP4i diabetic BP and the non-DPP4i diabetic 182 
BP (data not shown), an observation suggesting that presentation and initial severity of BP in 183 
these two groups were similar.   184 
DPP4i and BP 185 
The univariate analysis of the association between DPP4i use and BP in diabetic patients 186 
found an OR of 3.45 (95% CI: 1.76-6.77; p <0.001). After adjustment for possible 187 
confounding factors associated to BP onset and DPP4i use in multivariate analysis, the OR 188 
was 2.64 (95% CI: 1.19-5.85; p = 0.02) (Table 3).  189 
A more detailed analysis of DPP4i use found a higher association for vildagliptin, with a 190 
crude OR of 7.23 (95% CI: 2.44-21.40; p = 0.001) and an adjusted OR of 3.57 (95% CI: 1.07-191 
11.84; p = 0.04). The study was underpowered to detect differences between other DPP4i, 192 
linagliptin and alogliptin being only used in the Swiss cases. 193 
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Gender-stratified analysis indicated that the effect of DPP4i on BP onset was higher in males 194 
(adjusted OR = 4.36; 95% CI: 1.38-13.83; p = 0.01) than females (adjusted OR = 1.64; 95% 195 
CI: 0.53-5.11; p = 0.39). Age group-stratified analyses showed a stronger association for 196 
patients aged 80 years or older, with an adjusted OR of 5.31 (95% CI: 1.60-17.62; p = 0.006).  197 
Clinical course of BP patients under DPP4i 198 
In our three centers, we collected in total 28 diabetic patients developing BP under DPP4i 199 
exposure. The duration of DPP4i use and onset of BP ranged from 10 days until 3 years 200 
(median = 8.2 months). 201 
Drug withdrawal was performed in 19 patients on suspected DPP4i-associated BP. Complete 202 
(11/19; 58%) or partial (7/19; 37%) remission with some mild persistent disease was obtained 203 
for all patients but one (duration of follow up 3-30 months, median= 16.4 months). First-line 204 
treatment was high potency topical steroids and systemic corticosteroids in severe or 205 
refractory cases followed by a standard tapering schedule (5, 6). No further therapy was 206 
necessary in these patients after DPP4i withdrawal to obtain BP remission. For one patient, 207 
sitagliptin was initially stopped, leading to a partial remission, but its reintroduction combined 208 
with metformin led to a relapse of the BP. Definitive discontinuation of sitagliptin and its 209 
replacement by repaglinide resulted in a partial remission of BP with 12-month follow-up. 210 
The clinical outcome in the nine patients, in which DPP4i were not stopped, was unfavorable. 211 
There were three deaths of unknown causes (33%), one relapse (11%), four partial remissions 212 
(45%), and one complete remission (11%). 213 
214 
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Discussion 215 
Our study demonstrates that DPP4i are associated with an increased risk of developing BP, 216 
with an adjusted OR of 2.64. Association with vildagliptin was significantly higher compared 217 
to that with other DPP4i with an adjusted OR of 3.57. Our findings further indicate that the 218 
rate of DPP4i intake in patients with BP is higher both in male patients and in patients older 219 
than 80 years. Finally, DPP4i withdrawal seems to have a favorable impact on the outcome of 220 
BP diabetic patients, as 95% of them went into remission after management with first-line 221 
therapeutic options (ie, topical and sometimes systemic corticosteroids). 222 
An increasing number of reports have suggested that DPP4i trigger BP. Fourteen (74%) out of 223 
the 19 described BP cases appeared to be related to vildagliptin intake. The median age of 224 
affected patients was 72.5 years with an almost identical number of males and females (8-16). 225 
In our study, among the 28 diabetic patients developing BP under DPP4i exposure, males 226 
were more affected (56.7%) and the median age was 80 years.  227 
Garcia et al. (8) identified 170 cases of BP in patients on DPP4i in the EudraVigilance 228 
database, suggesting that the intake of DPP4i was more frequently associated with the 229 
development of BP when compared to that of other drugs. In the latter, a disproportionally 230 
high number cases using vildagliptin were found. A French case-non-case study recording all 231 
spontaneous reports of DPP4i-related BP in the National Pharmacovigilance Database 232 
between 04/2008 and 08/2014 also provided evidence for an increased risk of BP associated 233 
to DPP4i exposure, especially vildagliptin (7). Our present study confirms that the association 234 
with vildagliptin is stronger than that for the other DPP4i. This cannot be explained by an 235 
overprescription of vildagliptin compared to that of other DPP4i. In our control group, 236 
sitagliptin was the most prescribed DPP4i with 14 diabetic patients (11.5%), whereas only 5 237 
patients were treated by vildagliptin (4%). Increased prescribing of sitaglipitin was confirmed 238 
by an analysis of drug sales in France published by the ANSM (French National Agency for 239 
Medicines and Health Products Safety) in 2014. In this survey, sitagliptin was the most 240 
prescribed DPP4i and the 24th highest earning drug in 2013, whereas vildagliptin was not 241 
ranked. A recent retrospective study suggests that DPP4i-associated BP is frequently non- or 242 
pauci- inflammatory characterized by small blisters, mild erythema, and a limited skin 243 
distribution. The latter is potentially related to a distinct reactivity profile of autoantibodies to 244 
BP180 (17).  Although in our retrospective evaluation, there was no apparent difference in 245 
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clinical presentation and initial management between DPP4i diabetic BP patients and non-246 
DPP4i diabetic BP patients (data not shown), prospective studies are required to address the 247 
question whether BP associated with the intake of DPP4i has unique clinical and 248 
immunological features. 249 
The pathophysiological mechanisms linking DPP4i intake and BP development remain 250 
unclear. DPP4i could induce BP de novo or accelerate the development of BP in susceptible 251 
individuals. Many cell types, including keratinocytes, T-cells and endothelial cells, 252 
constitutionally express DPP4. DPP4 inhibition could enhance the activity of 253 
proinflammatory chemokines, like eotaxin, promoting eosinophil activation in the skin, tissue 254 
damage and blister formation (18). Thielitz et al. reported that DPP4i have an antifibrogenic 255 
activity by decreasing TGF-β1 expression and secretion of procollagen type I (19). All these 256 
effects could be higher for vildagliptin than other DPP4i due to molecular differences. 257 
Furthermore, vildagliptin administration in monkeys resulted in dose-dependent and 258 
reversible skin effects, such as blister formation, peeling, and erosions (20).  259 
Finally and more importantly, DPP4 is a cell surface plasminogen receptor that is able to 260 
activate plasminogen leading to plasmin formation. Plasmin is a major serine protease that is 261 
known to cleave BP180 within the juxtamembranous extracellular noncollagenous 16A 262 
domain. Hence, the inhibition of plasmin by DPP4i may change the proper cleavage of 263 
BP180, affecting by this means its antigenicity and its function (17). 264 
Our study has some limitations: we focused the analysis on DPP4i intake, while the potential 265 
isolated effect of metformin was not analyzed. Nevertheless, after DPP4i withdrawal, 266 
metformin was either continued (in those cases in which it was initially combined with 267 
DPP4i) or newly started in 8 of our BP patients. Among the latter, we observed 5 complete 268 
and three partial remissions on follow-up. In addition, metformin intake has not been 269 
implicated so far in the development of BP. Based on these observations, it is unlikely that 270 
metformin plays a triggering role but specific studies should be designed to examine the effect 271 
of metformin on its own. Finally, we included BP patients identified by searching our 272 
histopathology databases. It is therefore possible that we missed a number of BP cases in 273 
which either the term “pemphigoid” was not used in the corresponding histopathological 274 
report or BP was not clinically and/or histopathologically considered. 275 
In conclusion, our findings in a case-control study confirm that DPP4i are associated with an 276 
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increased risk of developing BP in diabetic patients. Therefore, the prescription of DPP4i, 277 
especially vildagliptin, should potentially be limited or avoided in high-risk patients, 278 
including males and those aged 80 years or older. A larger prospective study might be useful 279 
to confirm our findings.  280 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
13 
 
 
Abbreviations:  281 
BP, Bullous pemphigoid  282 
DPP4i, Dipeptidyl peptidase-IV inhibitors 283 
OR, Odds ratio 284 
CI, Confidence interval 285 
SD, Standard deviation  286 
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Table 1 - Demographics and comorbidities of selected cases and controls 362 
 363 
 Controls Cases Total p* 
N % N % N % 
Gender Male 60 49.2% 30 49.2% 90 49.2% - 
Female 62 50.8% 31 50.8% 93 50.8%  
Age, yrs (mean, SD) 79.3 7.0 78.7 7.2 79.1 7.0 0.63 
 < 75 30 24.6% 17 27.9% 47 25.7%  
75 - 84 62 50.8% 29 47.5% 91 49.7%  
85+ 30 24.6% 15 24.6% 45 24.6%  
Comorbidities Neurological 47 38.5% 32 52.5% 79 43.2% 0.06 
Cardiovascular 108 88.5% 53 86.9% 161 88.0% 0.75 
Rheumatic 36 29.5% 11 18.0% 47 25.7% 0.10 
Digestive 34 27.9% 19 31.1% 53 29.0% 0.65 
Metabolic and 
endocrine** 85 69.7% 24 39.3% 109 59.6% 
<0.001 
Pulmonary 27 22.1% 17 27.9% 44 24.0% 0.41 
Uronephrological 45 36.9% 24 39.3% 69 37.7% 0.74 
Neoplasia 29 23.8% 12 19.7% 41 22.4% 0.49 
Dermatological*** 5 4.1% 12 19.7% 17 9.3% 0.03 
Other  35 28.7% 23 37.7% 58 31.7% 0.18 
SD: standard deviation, yrs: years 364 
* Mann-Whitney U test was used to assess possible residual differences in the distribution of 365 
age between cases and age and gender matched controls. Differences between cases and 366 
matched controls across different levels of other factors were assessed by means of univariate 367 
conditional logistic regression analysis. 368 
** except for diabetes 369 
*** except for BP  370 
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Table 2- DPP4i use and other co-treatments in selected cases and controls 371 
 372 
 Controls Cases Total P* 
N % N % N % 
DPP4i None 100 82.0% 33 54.1% 133 72.7% <0.001 
Vildagliptin 5 4.1% 14 23.0% 19 10.4%  
Sitagliptin 14 11.5% 10 16.4% 24 13.1%  
Linagliptin 3 2.5% 3 4.9% 6 3.3%  
Saxagliptin 0 0.0% 1 1.6% 1 0.5%  
Co-
treatments 
Diuretics 69 56.6% 28 45.9% 97 53.0% 0.17 
Antihypertensives/ 
antiarrhythmic agents 101 82.8% 47 77.0% 148 80.9% 
0.36 
Neuroleptics 46 37.7% 26 42.6% 72 39.3% 0.52 
Antiaggregants/ 
anticoagulants 85 69.7% 45 73.8% 130 71.0% 
0.56 
NSAIDs 12 9.8% 0 0.0% 12 6.6% 0.14 
Analgesics 22 18.0% 12 19.7% 34 18.6% 0.79 
Statins 71 58.2% 31 50.8% 102 55.7% 0.34 
Antihistamines 5 4.1% 19 31.1% 24 13.1% <0.001 
Anti-diabetics** 122 100.0% 51 83.6% 173 94.5% 0.08 
Endocrine or metabolic 
treatment*** 
45 36.9% 27 44.3% 72 39.3% 0.32 
Proton pump inhibitors 59 48.4% 28 45.9% 87 47.5% 0.75 
Others 50 41.0% 23 37.7% 73 39.9% 0.67 
** except for DPP4i 373 
*** except for diabetes  374 
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Table 3 - Univariate and multivariate analysis of the association between DPP4i use and BP 375 
in diabetic patients, overall and in strata of gender and age group 376 
 377 
Strata DPP4i use  
Controls 
Cases Univariate 
analysis* 
Multivariable 
analysis** 
N % N % 
OR (95% 
CI) 
p 
OR (95% 
CI) 
p 
Overall No 100 82.0% 33 54.1% 1  1  
Yes 22 18.0% 28 45.9% 3.45 (1.76 
- 6.77) 
<0.001 2.64 (1.19 
- 5.85) 
0.02 
Overall 
(detailed) 
No 100 82.0% 33 54.1% 1  1  
Vildagliptin 5 4.1% 14 23.0% 7.23 (2.44 
- 21.40) 
<0.001 3.57 (1.07 
- 11.84) 
0.04 
Sitagliptin 14 11.5% 10 16.4% 1.82 (0.73 
- 4.54) 
0.20 2.13 (0.77 
- 5.89) 
0.15 
Linagliptin/ 
Saxagliptin 3 2.5% 4 6.6% 
5.10 (0.98 
- 26.62) 0.053 
2.90 (0.47 
- 17.74) 0.25 
Males No 51 85.0% 13 43.3% 1  1  
Yes 9 15.0% 17 56.7% 5.85 (2.13 
- 16.08) 
0.001 4.36 (1.38 
- 13.83) 
0.01 
Females No 49 79.0% 20 64.5% 1  1  
Yes 13 21.0% 11 35.5% 2.00 (0.78 
- 5.15) 
0.15 1.64 (0.53 
- 5.11) 
0.39 
Age <80 
yrs 
No 49 79.0% 18 56.2% 1  1  
Yes 13 21.0% 14 43.8% 2.47 (1.00 
- 6.13) 
0.05 1.53 (0.52 
- 4.52) 
0.44 
Age ≥80 
yrs 
No 51 85.0% 15 51.7% 1  1  
Yes 9 15.0% 14 48.3% 4.50 (1.58 
- 12.77) 
0.005 5.31 (1.60 
- 17.62) 
0.006 
OR: odds ratio, CI: confidence interval, yrs: years 378 
* Univariate conditional logistic regression analysis 379 
** Multivariable conditional logistic regression analysis including terms for neurological, 380 
metabolic/endocrine and other dermatological comorbidities 381 
